Softbank, Amgen-Backed Neumora Therapeutics Unveils Plans For Three Phase 3 Studies For Major Depressive Disorder
Portfolio Pulse from Vandana Singh
Neumora Therapeutics, backed by Softbank Group Corp and Amgen Inc, has announced plans for three Phase 3 studies for its major depressive disorder (MDD) candidate Navacaprant. The studies will evaluate the once-daily navacaprant oral monotherapy for MDD, with the first trial expected to start in 3Q23. The announcement follows the successful completion of a Phase 2 study with navacaprant, which showed promising results in reducing symptoms of depression.
July 18, 2023 | 6:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's equity investment in Neumora Therapeutics could yield positive returns if the Phase 3 trials of Navacaprant are successful.
Amgen, as an investor in Neumora Therapeutics, could see potential returns if the Phase 3 trials of Navacaprant are successful. The success of the trials and subsequent approval of Navacaprant could lead to increased revenues for Neumora, and by extension, potential returns for Amgen.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Softbank's investment in Neumora Therapeutics could see potential returns if the Phase 3 trials of Navacaprant are successful.
As an investor in Neumora Therapeutics, Softbank stands to benefit from the success of the Phase 3 trials. If the trials are successful and Navacaprant is approved for use, it could lead to increased revenues for Neumora, and by extension, potential returns for Softbank.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70